Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference

/PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, will...

Related Keywords

Lin Zhou ,Xizang ,China ,Australia ,Tianjin ,Xiaoxia ,Jiangxi ,Philadelphia ,Pennsylvania ,United States ,Suzhou ,Jiangsu ,University Of Pennsylvania ,Wenru ,Hainan ,Bern ,Switzerland ,Cambridge ,Cambridgeshire ,United Kingdom ,South Korea ,Chaomei ,Xiang Gao ,Gansu ,Chinese ,Frederick Beddingfield ,Sayaka Sato ,Dongqiong Fei ,Madhu Golla ,Takashi Miwa ,Bingbing Jiang ,Helen Fu ,Xihua Zhu ,Ajay Ma ,Damodar Gullipalli ,Richard Lee ,Fengkui Zhang ,Jianjun Zhang ,Prnewswire Kira Pharmaceuticals ,David Geffen School Of Medicine ,Institute Of Hematology ,Department Of Systems Pharmacology ,Perelman School Of Medicine ,Kira Pharmaceuticals ,Division Of Dermatology ,Chinese Academy Of Medical Sciences ,Department Of Medicine ,Human Disease ,Perelman School ,Akira President ,Co Founder Wenru Song ,Scientific Session ,Systems Pharmacology ,Translational Therapeutics ,Suzhou China ,David Geffen School ,Poster Viewing Session ,Chinese Academy ,Medical Sciences ,Wen Chao Song ,Kira Scientific Advisory Board ,